🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

67 results for “ADC” Clear

  1. Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Padcev 30 mg powder for concentrate for solution for infusion, Zimberelimab, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, DOMVANALIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences International Limited

    Locally Advanced/Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  2. Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co

    Boehringer Ingelheim International GmbH

    gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

    phase 2 small molecule active

    1 trial

  3. HuMax-TF-ADC, CARBOPLATIN , PEMBROLIZUMAB , BEVACIZUMAB

    Genmab A/S

    Recurrent or stage IVB cervical cancer

    phase 2 small molecule active

    1 trial

  4. Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1,200 mg concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Roche Registration Limited

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  5. Loncastuximab Tesirine

    ADC Therapeutics SA

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    4 trials

  6. Loncastuximab Tesirine

    ADC Therapeutics SA

    Waldenstrom Macroglobulinemia

    phase 2 small molecule active

    1 trial

  7. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed or Refractory Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  9. Loncastuximab tesirine

    ADC Therapeutics SA

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  10. Loncastuximab tesirine

    ADC Therapeutics SA

    Post-transplant Lymphoproliferative Disorder

    phase 2 small molecule active

    1 trial

  11. Loncastuximab tesirine

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma Refractory

    phase 2 small molecule completed

    1 trial

  12. Loncastuximab tesirine 150 µg/Kg

    ADC Therapeutics SA

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  13. Padcev 30 mg powder for concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    locally advanced or metastatic penile squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  14. Padcev 30 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Padcev 20 mg powder for concentrate for solution for infusion

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  15. Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  16. Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  17. RC48- ADC

    China SXT Pharmaceuticals

    Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance

    phase 2 small molecule active

    1 trial

  18. gene therapy

    PTC THERAPEUTICS, INC.

    Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

    phase 2 small molecule completed

    1 trial

  19. imvotamab

    ADC Therapeutics SA

    Non-Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  20. A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

    SUTRO BIOPHARMA, INC.

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 1 other active

    1 trial

  21. A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

    ADC Therapeutics SA

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  22. ADCLEC.syn1 CAR T cells

    Takeda Pharmaceuticals International AG

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  23. ADCT-301

    ADC Therapeutics SA

    Head and Neck Cancer Squamous Cell Carcinoma

    phase 1 small molecule terminated

    1 trial

  24. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources